UCSF UC San Francisco Electronic Theses and Dissertations
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Annual Report
Zentralinstitut für Seelische Gesundheit Landesstiftung des öffentlichen Rechts 2017 2019 ANNUAL REPORT 2017 2019 ANNUAL REPORT EXECUTIVE BOARD RESEARCH REPORT BY THE EXECUTIVE BOARD, DEPARTMENTS, INSTITUTES DEVELOPMENT FIGURES AND RESEARCH GROUPS Report by the Executive Board 6 The Future of Therapy Research 42 Development Figures 8 Department of Neuropeptide Research 46 in Psychiatry Department of Molecular Neuroimaging 47 Department of Public Mental Health 48 Hector Institute for Translational 50 Brain Research RG Developmental Brain Pathologies 51 Department of Biostatistics 52 PATIENT CARE Institute of Cognitive and 53 Clinical Neuroscience CLINICAL DEPARTMENTS AND INSTITUTES RG Brain Stimulation, Neuroplasticity and 54 Learning RG Psychobiology of Risk Behavior 54 Clinic of Psychiatry and Psychotherapy 12 RG Body Plasticity and Memory Processes 55 Clinic of Child and Adolescent Psychiatry and 20 RG Psychobiology of Pain 56 Psychotherapy RG Psychobiology of Emotional Learning 57 Clinic of Psychosomatic Medicine and 24 Institute for Psychopharmacology 58 Psychotherapy RG Behavioral Genetics 59 RG Translational Addiction Research 60 Clinic of Addictive Behavior and 26 RG Physiology of Neuronal Networks 61 Addiction Medicine RG Molecular Psychopharmacology 62 Adolescent Center for Disorders 29 RG Neuroanatomy 63 of Emotional Regulation RG In Silico Psychopharmacology 64 Adolescent Center for 30 Institute for Psychiatric and 65 Psychotic Disorders – SOTERIA Psychosomatic Psychotherapy RG Experimental Psychotherapy 66 Central Outpatient -
The “Rights” of Precision Drug Development for Alzheimer's Disease
Cummings et al. Alzheimer's Research & Therapy (2019) 11:76 https://doi.org/10.1186/s13195-019-0529-5 REVIEW Open Access The “rights” of precision drug development for Alzheimer’s disease Jeffrey Cummings1*, Howard H. Feldman2 and Philip Scheltens3 Abstract There is a high rate of failure in Alzheimer’s disease (AD) drug development with 99% of trials showing no drug- placebo difference. This low rate of success delays new treatments for patients and discourages investment in AD drug development. Studies across drug development programs in multiple disorders have identified important strategies for decreasing the risk and increasing the likelihood of success in drug development programs. These experiences provide guidance for the optimization of AD drug development. The “rights” of AD drug development include the right target, right drug, right biomarker, right participant, and right trial. The right target identifies the appropriate biologic process for an AD therapeutic intervention. The right drug must have well-understood pharmacokinetic and pharmacodynamic features, ability to penetrate the blood-brain barrier, efficacy demonstrated in animals, maximum tolerated dose established in phase I, and acceptable toxicity. The right biomarkers include participant selection biomarkers, target engagement biomarkers, biomarkers supportive of disease modification, and biomarkers for side effect monitoring. The right participant hinges on the identification of the phase of AD (preclinical, prodromal, dementia). Severity of disease and drug mechanism both have a role in defining the right participant. The right trial is a well-conducted trial with appropriate clinical and biomarker outcomes collected over an appropriate period of time, powered to detect a clinically meaningful drug-placebo difference, and anticipating variability introduced by globalization. -
Triptans Step Therapy/Quantity Limit Criteria
Triptans Step Therapy/Quantity Limit Criteria Program may be implemented with the following options 1) step therapy 2) quantity limits or 3) step therapy with quantity limits For Blue Cross and Blue Shield of Illinois Option 1 (step therapy only) will apply. Brand Generic Dosage Form Amerge® naratriptan tablets Axert® almotriptan tablets Frova® frovatriptan tablets Imitrex® sumatriptan injection*, nasal spray, tablets* Maxalt® rizatriptan tablets Maxalt-MLT® rizatriptan tablets Relpax® eletriptan tablets Treximet™ sumatriptan and naproxen tablets Zomig® zolmitriptan tablets, nasal spray Zomig-ZMT® zolmitriptan tablets * generic available and included as target agent in quantity limit edit FDA APPROVED INDICATIONS1-7 The following information is taken from individual drug prescribing information and is provided here as background information only. Not all FDA-approved indications may be considered medically necessary. All criteria are found in the section “Prior Authorization Criteria for Approval.” Amerge® Tablets1, Axert® Tablets2, Frova® Tablets3,Imitrex® injection4, Imitrex Nasal Spray5, Imitrex Tablets6, Maxalt® Tablets7, Maxalt-MLT® Tablets7, Relpax® Tablets8, Treximet™ Tablets9, Zomig® Tablets10, Zomig-ZMT® Tablets10, and Zomig® Nasal Spray11 Amerge (naratriptan), Axert (almotriptan), Frova (frovatriptan), Imitrex (sumatriptan), Maxalt (rizatriptan), Maxalt-MLT (rizatriptan orally disintegrating), Relpax (eletriptan), Treximet (sumatriptan/naproxen), Zomig (zolmitriptan), and Zomig-ZMT (zolmitriptan orally disintegrating) tablets, and Imitrex (sumatriptan) and Zomig (zolmitriptan) nasal spray are all indicated for the acute treatment of migraine attacks with or without aura in adults. They are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. Safety and effectiveness of all of these products have not been established for cluster headache, which is present in an older, predominantly male population. -
La Place Des Composés Multi Target Directed Ligands Dans Le Traitement De La Maladie D’Alzheimer Katia Hamidouche
La place des composés Multi Target Directed Ligands dans le traitement de la maladie d’Alzheimer Katia Hamidouche To cite this version: Katia Hamidouche. La place des composés Multi Target Directed Ligands dans le traitement de la maladie d’Alzheimer. Sciences pharmaceutiques. 2017. dumas-01556379 HAL Id: dumas-01556379 https://dumas.ccsd.cnrs.fr/dumas-01556379 Submitted on 5 Jul 2017 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. UNIVERSITE DE CAEN NORMANDIE ANNEE 2017 U.F.R. DES SCIENCES PHARMACEUTIQUES THESE POUR LE DIPLOME D’ETAT DE DOCTEUR EN PHARMACIE PRESENTEE PAR Katia HAMIDOUCHE SUJET : La place des composés "Multi Target Directed Ligands" dans le traitement de la maladie d'Alzheimer SOUTENUE PUBLIQUEMENT LE : 31/03/2017 JURY : Pr. Michel Boulouard PRESIDENT DU JURY Dr. Véronique Lelong Boulouard EXAMINATEUR Dr. Joanna Bourgine EXAMINATEUR Pr. Thomas Freret Remerciements Avant tout, je tiens à dédier ce travail à mes parents , que je remercie également profondément pour leurs longs encouragements et soutien, et à qui je présente toute ma reconnaissance et gratitude pour les sacrifices qu’ils ont choisis de faire afin de nous permettre, ma sœur, mes frères et moi -même de faire ces grandes études, et sans lesquels je n’aurai jamais découvert cet univers de savoir et de science « à la Française ». -
Medication Guide 2012
DeKalb County D.U.I. Court Supervised Treatment Program MEDICATION GUIDE Medication Guide 2012 DeKalb County State Court Decatur, Georgia xxi ********** WELCOME TO THE DEKALB COUNTY D.U.I. COURT SUPERVISED TREATMENT PROGRAM. This 2012 Medication Guide was developed as a collaborative effort by Becky Pirouz, Pharm.D., Director of Pharmacy, Peachford Hospital, and by Lois Michalove, Treatment Coordinator for the DeKalb County D.U.I. Court Supervised Treatment Program, both of whom have extensive experience in addiction recovery and treatment. ********** The following information is intended to assist you in making decisions about medications. This may include those medications that you are prescribed and/or your selection of over-the-counter (OTC) products. Unintended exposure may compromise your treatment program. This is not an exhaustive list, but contains some of the medications that are most commonly used. If in doubt, always consult the Treatment Coordinator. Please inform your physician, dentist, pharmacist and other health care professionals that you are in a recovery program. WE ARE A ZERO-TOLERANCE PROGRAM! DO NOT COMPROMISE YOUR RECOVERY BY MAKING HIGH-RISK CHOICES! xxii - Section 1 – Drugs To Avoid The following drugs must not be used at any time. They are well known to be abused and even small amounts may result in relapse and are contraindicated in your treatment program. However, extenuating circumstances may occur which necessitates the short- term limited use of some of the drugs on this list in consultation with your physician, the Judge and the Treatment Coordinator. This decision should be made prior to your ingestion of any of the Drugs to Avoid. -
Triazolobenzodiazepines and -Triazepines As Protein Interaction Inhibitors Targeting Bromodomains of the BET Family
Dissertation zur Erlangung des Doktorgrades der Fakultät für Chemie und Pharmazie der Ludwig-Maximilians-Universität München Triazolobenzodiazepines and -triazepines as Protein Interaction Inhibitors Targeting Bromodomains of the BET Family Matthias Alfons Wrobel aus Weiden i.d.OPf. 2013 Erklärung Diese Dissertation wurde im Sinne von § 7 der Promotionsordnung vom 28. November 2011 von Herrn Prof. Dr. Franz Bracher betreut. Eidesstattliche Versicherung Diese Dissertation wurde eigenständig und ohne unerlaubte Hilfe erarbeitet. München, 09.12.2013 Matthias Wrobel Dissertation eingereicht am 10.12.2013 1. Gutachter: Prof. Dr. Franz Bracher 2. Gutachter: Prof. Dr. Stefan Knapp Mündliche Prüfung am 21.01.2014 This dissertation was carried out in close collaboration with the Structural Genomics Consortium of the University of Oxford. Prof. Dr. Stefan Knapp Dr. Panagis Filippakopoulos Screening via DSF / ITC / Co-crystallization …für Caro …für meine Familie Acknowledgements I would like to thank Prof. Dr. Franz Bracher for giving me the possibility to work on this interesting topic, the helpful advices in meetings, always having a sympathetic ear for all kind of affairs and his support during the time of my PhD Thesis. I would also like to thank all the members of the Board of Examiners. In gratitude for the opportunity to visit his group at the University of Oxford (UK) and his considerable commitment for our collaboration, I would like to thank Prof. Dr. Stefan Knapp. Special thanks goes to Dr. Panagis Filippakopoulos for his supervision during my stays at the SGC and his patience and support in uncountable discussions about co-crystallization, structure optimization and critical appraisal of screening results. -
Copyrighted Material
Index Note: page numbers in italics refer to figures; those in bold to tables or boxes. abacavir 686 tolerability 536–537 children and adolescents 461 acamprosate vascular dementia 549 haematological 798, 805–807 alcohol dependence 397, 397, 402–403 see also donepezil; galantamine; hepatic impairment 636 eating disorders 669 rivastigmine HIV infection 680 re‐starting after non‐adherence 795 acetylcysteine (N‐acetylcysteine) learning disability 700 ACE inhibitors see angiotensin‐converting autism spectrum disorders 505 medication adherence and 788, 790 enzyme inhibitors obsessive compulsive disorder 364 Naranjo probability scale 811, 812 acetaldehyde 753 refractory schizophrenia 163 older people 525 acetaminophen, in dementia 564, 571 acetyl‐L‐carnitine 159 psychiatric see psychiatric adverse effects acetylcholinesterase (AChE) 529 activated partial thromboplastin time 805 renal impairment 647 acetylcholinesterase (AChE) acute intoxication see intoxication, acute see also teratogenicity inhibitors 529–543, 530–531 acute kidney injury 647 affective disorders adverse effects 537–538, 539 acutely disturbed behaviour 54–64 caffeine consumption 762 Alzheimer’s disease 529–543, 544, 576 intoxication with street drugs 56, 450 non‐psychotropics causing 808, atrial fibrillation 720 rapid tranquillisation 54–59 809, 810 clinical guidelines 544, 551, 551 acute mania see mania, acute stupor 107, 108, 109 combination therapy 536 addictions 385–457 see also bipolar disorder; depression; delirium 675 S‐adenosyl‐l‐methionine 275 mania dosing 535 ADHD -
A [18F]Fluoroethoxybenzovesamicol Positron Emission Tomography Study
Received: 24 May 2018 Revised: 7 September 2018 Accepted: 10 September 2018 DOI: 10.1002/cne.24541 RESEARCH ARTICLE Regional vesicular acetylcholine transporter distribution in human brain: A [18F]fluoroethoxybenzovesamicol positron emission tomography study Roger L. Albin1,2,3,4 | Nicolaas I. Bohnen1,2,3,5 | Martijn L. T. M. Muller3,5 | William T. Dauer1,2,3,6 | Martin Sarter3,7 | Kirk A. Frey2,5 | Robert A. Koeppe3,5 1Neurology Service & GRECC, VAAAHS, Ann Arbor, Michigan Abstract 2Department of Neurology, University of Prior efforts to image cholinergic projections in human brain in vivo had significant technical lim- Michigan, Ann Arbor, Michigan itations. We used the vesicular acetylcholine transporter (VAChT) ligand [18F]fluoroethoxyben- 3University of Michigan Morris K. Udall Center zovesamicol ([18F]FEOBV) and positron emission tomography to determine the regional of Excellence for Research in Parkinson's distribution of VAChT binding sites in normal human brain. We studied 29 subjects (mean age Disease, Ann Arbor, Michigan 47 [range 20–81] years; 18 men; 11 women). [18F]FEOBV binding was highest in striatum, inter- 4Michigan Alzheimer Disease Center, Ann Arbor, Michigan mediate in the amygdala, hippocampal formation, thalamus, rostral brainstem, some cerebellar 18 5Department of Radiology, University of regions, and lower in other regions. Neocortical [ F]FEOBV binding was inhomogeneous with Michigan, Ann Arbor, Michigan relatively high binding in insula, BA24, BA25, BA27, BA28, BA34, BA35, pericentral cortex, and 6Department of Cell and Developmental lowest in BA17–19. Thalamic [18F]FEOBV binding was inhomogeneous with greatest binding in Biology, University of Michigan, Ann Arbor, the lateral geniculate nuclei and relatively high binding in medial and posterior thalamus. -
In Alzheimer Disease: Never Change a Winning Team and Do Not Build Exclusively on Surrogates
Journal of Pharmacology & Clinical Research ISSN: 2473-5574 Review Article J of Pharmacol & Clin Res Volume 2 Issue 1 - February 2017 Copyright © All rights are reserved by Jan M Keppel Hesselink DOI: 10.19080/JPCR.2017.02.555580 Idalopirdine (LY483518, SGS518, Lu AE 58054) in Alzheimer disease: never change a winning team and do not build exclusively on surrogates. Lessons Learned from Drug Development Trials Jan M Keppel Hesselink* Department of Molecular Pharmacology, University Witten/Herdecke, Germany Submission: January 11, 2017; Published: February 07, 2017 *Corresponding author: Jan M Keppel Hesselink, Department of Molecular Pharmacology, University Witten/Herdecke, Germany, Email: Abstract The effect of Acetylcholinesterase inhibition on Alzheimer’s disease is modest. Augmentation strategies are thus whished for and explored. acetylcholinesterase inhibitors in animal pharmacology. A phase Idalopirdine is a 5HT6 antagonist, and was found to augment the efficacy of II study supported the concept, however the study did not follow a dose-finding design, but focused on one dose only, 90 mg/daily. Currently Wea phase will discussIII program the phase further II andevaluates phase IIIthe program value of ofsuch idalopirdine augmentation in Alzheimer strategy. disease The first and phase outline III thetrial lessons however learned missed for the drug target. development: This first phase III trial was underdosed; maximum dose was 60 mg/daily, possibly based on an overly firm belief in surrogate parameters, a PET study. mg/day). Subsequently do not change the dose-regime from t.i.d. in phase II to once daily in phase III, even if surrogate parameters support always use fixed dose range studies in phase II, first define the lowest effective dose and the no-effect dose, as well as the effective dose (90 conservative drug development pattern and avoid cutting corners seems the lesson of this case of idalopirdine in Alzheimer disease. -
BET Bromodomain Protein Inhibition Is a Therapeutic Option for Medulloblastoma
www.impactjournals.com/oncotarget/ Oncotarget, November, Vol.4, No 11 BET bromodomain protein inhibition is a therapeutic option for medulloblastoma Anton Henssen1, Theresa Thor2,4, Andrea Odersky 1, Lukas Heukamp6, Nicolai El- Hindy7, Anneleen Beckers8, Frank Speleman8, Kristina Althoff1, Simon Schäfers1, Alexander Schramm1, Ulrich Sure7, Gudrun Fleischhack1, Angelika Eggert9, Johannes H. Schulte1,5 1 Department of Pediatric Oncology and Hematology, University Children`s Hospital Essen, Essen, Germany 2 German Cancer Consortium (DKTK), Germany 3 Translational Neuro-Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany 4 German Cancer Research Center (DKFZ), Heidelberg, Germany 5 Centre for Medical Biotechnology, University Duisburg-Essen, Essen, Germany 6 Institute of Pathology, University Hospital Cologne, Cologne, Germany 7 Department of Neurosurgery, University of Essen, Essen, Germany 8 Center of Medical Genetics Ghent (CMGG), Ghent University Hospital, Ghent, Belgium 9 Department of Pediatric Oncology/Hematology, Charité-Universitätsmedizin Berlin, Germany Correspondence to: Johannes H. Schulte, email: [email protected] Keywords: BET bromodomains, BRD4, MYC, JQ1, pediatric brain tumors, targeted therapy Received: October 23, 2013 Accepted: October 25, 2013 Published: October 27, 2013 This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT: Medulloblastoma is the most common malignant brain tumor of childhood, and represents a significant clinical challenge in pediatric oncology, since overall survival currently remains under 70%. Patients with tumors overexpressing MYC or harboring a MYC oncogene amplification have an extremely poor prognosis. Pharmacologically inhibiting MYC expression may, thus, have clinical utility given its pathogenetic role in medulloblastoma. -
Macrophage Inflammatory Responses BET Inhibitor JQ1 Impair Mouse
BET Protein Function Is Required for Inflammation: Brd2 Genetic Disruption and BET Inhibitor JQ1 Impair Mouse Macrophage Inflammatory Responses This information is current as of October 4, 2021. Anna C. Belkina, Barbara S. Nikolajczyk and Gerald V. Denis J Immunol 2013; 190:3670-3678; Prepublished online 18 February 2013; doi: 10.4049/jimmunol.1202838 Downloaded from http://www.jimmunol.org/content/190/7/3670 Supplementary http://www.jimmunol.org/content/suppl/2013/02/19/jimmunol.120283 Material 8.DC1 http://www.jimmunol.org/ References This article cites 51 articles, 19 of which you can access for free at: http://www.jimmunol.org/content/190/7/3670.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on October 4, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology BET Protein Function Is Required for Inflammation: Brd2 Genetic Disruption and BET Inhibitor JQ1 Impair Mouse Macrophage Inflammatory Responses Anna C. -
A Phase IB Dose Exploration Trial with MK-8628, a Small
Official Protocol Title: A Phase IB Dose Exploration Trial with MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects with Selected Advanced Solid Tumors NCT number: NCT02698176 Document Date: 21-Nov-2016 Product: MK-8628 1 Protocol/Amendment No.: 006-02 THIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC., WHITEHOUSE STATION, NJ, U.S.A. SPONSOR: Oncoethix GmbH, a wholly owned subsidiary of Merck Sharp & Dohme Corp. (hereafter referred to as the Sponsor or Merck) Weystrasse 20 6000 Lucerne Switzerland Protocol-specific Sponsor Contact information can be found in the Investigator Trial File Binder (or equivalent). TITLE: A Phase IB Dose Exploration Trial with MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects with Selected Advanced Solid Tumors IND NUMBER: 123,715 EudraCT NUMBER: 2015-005488-18 MK-8628-006-02 Final Protocol 21-Nov-2016 Confidential Product: MK-8628 2 Protocol/Amendment No.: 006-02 TABLE OF CONTENTS SUMMARY OF CHANGES................................................................................................ 11 1.0 TRIAL SUMMARY.................................................................................................. 13 2.0 TRIAL DESIGN........................................................................................................ 14 2.1 Trial Design ..........................................................................................................